National Nanoscience Center to realize the transformation of nanodrug results

Recently, the National Nanoscience Center (hereinafter referred to as the Nano-Center) held in Beijing, "injection of hydrochloric acid Ilithikang (nano) beam" technology transfer summary briefingChina Science Daily reporter learned from the meeting, by the nano-center researchers for the latecolorectal cancerof the "injection hydrochloric acid Ilitikang (nano) gel beam drug", has been approved for clinical trialsThis is currently the first domestic approved to enter the clinical name contains the word "nano" therapeutic new drugat present, for advanced colorectal cancer, iliticon hydrochloric acid is a wide-ranging broad-spectrum drug of cytotoxicdrugs widely used in clinical practiceHowever, it has fatal diarrhea dehydration, abdominal spastic pain, fever and other side effectsNanodrugs have advantages in surface and dimensional effects and become the direction to solve this problemfor many years, nano-center researcher Liang Xingjie's team has been working on the construction of new nano-drugs and their application sand in the preventionand treatmentof major malignant diseases such as cancerSince 2012, with the special support of the Strategic Pilot Science and Technology of the Chinese Academy of Sciences, they have realized the hydrochloric acid Ilitinami with compatible biomaterials, effectively improved the encapsulation rate of the drug, and created a series of detection methods of the specific nature of nanopharmaceuticalsthe results of theresearch results show that the injection hydrochloric acid Iliticon (nano) adhesive beam preparation has the characteristics of "sponge buffer effect", can greatly reduce the combination of Ilitikon and plasma protein, reduce the nonspecific toxic side effects of free drugs, so that the drug maximum tolerable dose and exposure to tumor target tissue are greatly increased, the drug effect is significantly improvedThrough single and multiple drug-administered experiments in normal animals and lotus animals, the maximum tolerable dose of the gel formulation can reach 1.56 times more than the commercially available drug, and the anti-tumor effect is 2.45 timesafter many optimizations, Liang Xingjie team finally determined the hydrochloric acid Ilithikang (nano) adhesive beam formula, process and quality standards, later in the China Pharmaceutical Research and Development Center Co., Ltdin collaboration to complete the registration declarationApril 2020, NanoCenter signed a cooperation agreement with Guangdong Yuchu Medical Technology Co., Ltdto continue the clinical trial of ilitikang (nano) gel beam with anti-tumor class 2.2 new drug injectionThe transfer amount of the result exceeds RMB 100 millionSource: